Clinical Edge Journal Scan

Impact of female hormonal exposure on risk of RA


 

Key clinical point: Early age at first pregnancy (less than 22 years) and early menopause (45 years and earlier) were associated with a higher risk of rheumatoid arthritis (RA), whereas long-term progestogen use (more than 24 months) before menopause was associated with a reduced risk.

Major finding: The risk of RA was a significantly increased with early age at first pregnancy (less than 22 vs. 27 or more years; hazard ratio [HR], 1.34; Ptrend = .028) and menopause (45 or less vs. 53 or more years; HR, 1.40; Ptrend = .039). Risk of RA was inversely related to exposure to progestogen only in perimenopause (more than 24 vs. 0 months; multi-adjusted HR, 0.77; Ptrend = .004).

Study details: This study included 78,452 women, with 698 incident cases of RA using data from the French E3N-EPIC cohort study.

Disclosures: The study was funded by a research grant from FOREUM Foundation for Research in Rheumatology. The authors declared no conflicts of interest.

Source: Salliot C et al. Rheumatology (Oxford). 2021 Feb 6. doi: 10.1093/rheumatology/keab101 .

Recommended Reading

Rheumatologic disease activity an important influencer of COVID-19 death risk
MDedge Rheumatology
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
MDedge Rheumatology
COVID-19 vaccination recommended for rheumatology patients
MDedge Rheumatology
Methotrexate-associated hepatotoxicity risk differs between psoriasis, PsA, and RA patients
MDedge Rheumatology
ACR, AAD, AAO, RDS issue joint statement on safe use of hydroxychloroquine
MDedge Rheumatology
RA experts highlight key developments over the past year
MDedge Rheumatology
Filgotinib+MTX shows benefit in RA patients with inadequate response to MTX
MDedge Rheumatology
Anti-PAD3 positivity tied to higher disease activity and joint damage in RA
MDedge Rheumatology
Safety and efficacy of biosimilar CT-P17 and adalimumab in RA
MDedge Rheumatology
Modern treatment approach results in LDA and remission in pregnant patients with RA
MDedge Rheumatology